Kiora Pharmaceuticals, Inc.
NASDAQ: KPRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Brian Strem
- Employees
- 12
- Headquarters
- Encinitas, United States
- IPO year
- 2015
- Market cap
- $11.5M
- Website
- https://www.kiorapharma.com
Loading KPRX…
Loading profile data…Frequently asked questions about KPRX
What does Kiora Pharmaceuticals, Inc. (KPRX) do?
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovat...
Where does KPRX trade?
Kiora Pharmaceuticals, Inc. (KPRX) trades on the NASDAQ Capital Market.
What sector is KPRX in?
Kiora Pharmaceuticals, Inc. (KPRX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Kiora Pharmaceuticals, Inc.?
Brian Strem is the chief executive officer of Kiora Pharmaceuticals, Inc. (KPRX).
Where is Kiora Pharmaceuticals, Inc. headquartered?
Kiora Pharmaceuticals, Inc. is headquartered in United States.
Does KPRX pay a dividend?
Kiora Pharmaceuticals, Inc. (KPRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KPRX go public?
Kiora Pharmaceuticals, Inc. (KPRX) completed its initial public offering in 2015.